Product Information
REXULTI 3 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $49.5808 per EA under NDC 59148003913. Its NADAC has been published 528 times since May 18, 2016.
Strength
3 mg/1
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148003913
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
BREXPIPRAZOLEApproval Type
New Drug (NDA)
FDA Application
NDA205422On Market Since
7/10/2015
Pharmacological Classes
Price Statistics
The NADAC for REXULTI 3 MG TABLET has been published 528 times since May 18, 2016, and over the history we have for it it has risen 65.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $49.5808 per EA |
|---|---|
| All-time high | $49.6041 (May 13, 2026) |
| All-time low | $29.8723 (Jun 22, 2016) |
| 52-week high | $49.6041 |
| 52-week low | $48.3053 |
| Median price | $39.7418 |
| Average price | $40.0742 |
| Largest weekly change | +9.9% (Apr 11, 2018) |
| Weeks tracked | 528 |
| Tracking since | May 18, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the brexpiprazole market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of REXULTI 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REXULTI 3 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $49.5808 per EA (NDC 59148003913), effective Jun 24, 2026.
How has the price of REXULTI 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for REXULTI 3 MG TABLET has risen 65.7%. It has been tracked across 528 weekly CMS publications since May 18, 2016.
What are the highest and lowest recorded NADAC prices for REXULTI 3 MG TABLET?
Since May 18, 2016, the NADAC for REXULTI 3 MG TABLET has ranged from a low of $29.8723 (Jun 22, 2016) to a high of $49.6041 (May 13, 2026), with a median of $39.7418 per EA.
Are there cheaper alternatives to REXULTI 3 MG TABLET?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of REXULTI 3 MG TABLET, so no direct lower-cost alternative is listed.
Who manufactures REXULTI 3 MG TABLET?
REXULTI 3 MG TABLET (NDC 59148003913) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification